Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07205510
Recruiting Observational

Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)

NCT07205510 · tracked via the Priya Life Science China tracker
Sponsor
RenJi Hospital
Phase
Observational
Started
2020-12-01
Last updated
2025-10-03

Condition(s) studied

SarcopeniaMetabolic DiseasesAll-cause MortalityAgingCardiometabolic Diseases

Investigational drug(s) / intervention(s)

nothing

nothing: This is an observational study.

Study summary

This study aims to establish an ambispective cohort platform centered on the pathological axis of "sarcopenia-metabolic disorders-aging progression", integrating multimodal data including demographic characteristics, lifestyle factors, clinical phenotypes, laboratory tests, medical imaging, and biospecimens. Namely 'Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)'.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Adults aged 18 and over Exclusion Criteria: 1. Does not cooperate in signing the informed consent form; 2. Does not possess legal capacity; 3. In a state of loss of consciousness; 4. Suffering from severe mental illness, unable to communicate normally; 5. The researcher believes that the subject has a disease that affects the assessment of results and is unsuitable for inclusion.

Primary outcome measure(s)

  • all-cause mortality — From enrollment to the 5-year and 10-year follow-up visit.
    Collect information on all-cause mortality of patients through hospital medical records, telephone follow-ups, outpatient follow-ups, etc., in order to assess the combined effects and underlying mechanisms of sarcopenia, metabolic diseases, and aging on all-cause mortality.

Trial sites (1)

FacilityCityRegionStatus
Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. Shanghai China Recruiting

More RenJi Hospital trials in China

Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage Recruiting
Plasma DNA Methylation for Preoperative Classification of Renal Masses Recruiting
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma Starting soon
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer Recruiting
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases Starting soon

Other trials for the same condition

Cardiometabolic evalUation REgistry of Heart Failure Recruiting
Effect of Low Valine Diet on Body Weight and Metabolic Parameters Recruiting
Muscle Ultrasound for Sarcopenia Assessment in Kidney Transplant Recipients Starting soon
Chronic Kidney Disease-related Sarcopenia With Poor Prognosis Recruiting
Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07205510 on ClinicalTrials.gov ↗ ← All trials in China